NCI restructures government-supported cancer trials programme in US
This article was originally published in Scrip
The US National Cancer Institute has announced major changes to the government-supported Cancer Trials Cooperative Group Program that conducts many of the trials of new cancer therapies. As part of the overhaul, the NCI – part of the National Institutes of Health – intends to consolidate the nine groups that currently conduct trials in adult cancer patients into four state-of-the art entities that will design and perform improved trials of cancer therapies.
You may also be interested in...
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-four guidance documents have been posted on the tracker since its last update.
The risk of psychiatric disorders with chloroquine and hydroxychloroquine-containing medicines received renewed attention in the EU after they were being used as potential treatments for COVID-19.
New UK guidance explains how clinical trial sponsors and investigator sites can ensure that trial monitors securely process data in electronic health record systems that do not have a restricted access functionality.